Clinical trials
Follow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
MT1013
- Development stage
- Phase 3
- Lead developer
- Shaanxi Micot Technology
- Modality
- Recombinant Proteins and Enzymes, Peptides
- Administration
- Intravenous
01
Overview
MT1013 is a synthetic bispecific peptide drug candidate developed for the treatment of secondary hyperparathyroidism (SHPT) in patients with chronic kidney disease (CKD) undergoing maintenance hemodialysis. It acts as an agonist of the calcium-sensing receptor (CaSR), and is also described as a functional osteogenic growth peptide (OGP) analogue. The drug is administered intravenously and is currently being evaluated in phase II clinical trials to assess its efficacy and safety for SHPT in CKD patients on hemodialysis. The developer of MT1013 is Shaanxi Micot Technology[1][2][3][4][5].
02
Targets
CaSR (Extracellular calcium-sensing receptor)PTH1R (Parathyroid hormone/Parathyroid hormone-related peptide receptor type 1)
Beyond the preview
Go deeper on MT1013.
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Indications & development
Explore development by indication, patient population, and geography.
- Indications
- Development status
- Countries
Licensing & deals
Trace asset ownership, licensing agreements, and commercial partnerships.
- Partners
- Deal terms
- Milestones
Patents & exclusivity
Explore the patent landscape and regulatory exclusivity around an asset.
- Patents
- Expiration dates
- Exclusivity
Competitive landscape
Compare development programs by target, modality, and indication.
- Competing assets
- Targets
- Development stage
Research & analysis
Connect source evidence and development news to your research questions.
- Publications
- News
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on MT1013.